- STAT+: Pharmalittle: We’re reading about Lilly obesity drug data, a push for FDA to ban DTC ads, and moreA study of Lilly's retatrutide weight loss drug in people with heart disease did not answer a crucial question — whether it reduces cardiovascular riskSTAT · 20h ago↗ source
- STAT+: HHS to convene experts on standards for clinical AIIn this edition of STAT Health Tech: HHS is inviting experts to shape policy on clinical AI, Whoop's new CMO, news about brain implants, and more.STAT · 21h ago↗ source
- Repligen’s $1.5B buy for BioLife; BeOne’s $300M US expansionPlus, news about Lonza, Bachem and Samsung Biologics. 🤝 Repligen to acquire BioLife Solutions: Repligen will pay around $1.5 billion for cell processing service supplier BioLife, 36% of which w…